Small molecule · Antagonist of neurokinin 3 receptor (TACR3) · developed by Acer Therapeutics
Osanetant is an orally bioavailable, brain-penetrating small-molecule antagonist of neurokinin 3 receptor (NK3R) that blocks NK3R-mediated signaling in the central nervous system. It is being studied to treat vasomotor symptoms in postmenopausal women and men on androgen deprivation therapy, and may suppress hormone secretion including testosterone, luteinizing hormone, and follicle-stimulating hormone.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05325775 | Phase 1/2 | Post-menopausal Vasomotor Symptoms | Completed | ZVRA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Post-menopausal Vasomotor Symptoms
See ZVRA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ZVRA catalysts and pipeline →